Share chart Molecular Partners AG
Extended chart
Simple chart
About Molecular Partners AG
Molecular Partners AG работает как биофармацевтическая компания на клинической стадии. Она разрабатывает Abicipar, терапевтический кандидат DARPin, который находится в фазе III клинических испытаний для лечения влажной возрастной дегенерации желтого пятна, а также диабетического отека желтого пятна; и MP0250, который связывает и ингибирует фактор роста сосудистого эндотелия и фактор роста гепатоцитов, что восстанавливает клиническую чувствительность к различным стандартным методам лечения множественной миеломы. more detailsIPO date | 2021-06-16 |
---|---|
ISIN | US60853G1067 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | chf |
Сайт | https://www.molecularpartners.com |
Цена ао | 5.29 |
Change price per day: | 0% (5.33) |
---|---|
Change price per week: | -4.05% (5.555) |
Change price per month: | +0.3766% (5.31) |
Change price per 3 month: | -17.49% (6.46) |
Change price per half year: | -33.38% (8) |
Change price per year: | +14.62% (4.65) |
Change price per 3 year: | -80.27% (27.01) |
Change price per 5 year: | 0% (5.33) |
Change price per 10 year: | 0% (5.33) |
Change price per year to date: | -0.3738% (5.35) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
BVF Inc. | 443 | 1.22 |
Suvretta Capital Management, LLC | 400 | 1.1 |
Morgan Stanley | 367 | 0 |
UBS Group AG | 326 | 0 |
Rhumbline Advisers | 269 | 0 |
Tang Capital Management, LLC | 100 | 0.27 |
Qube Research & Technologies Ltd | 16 | 0 |
Royal Bank of Canada | 2 | 0 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
SPDR Portfolio Europe ETF | 0.00088 | 8.94 | 3.66537 |
Avantis International Equity ETF | 0 | 6.46 | 3.80856 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board | N/A | 1972 (53 years) |
Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology | N/A | |
Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | N/A | |
Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board | N/A | 1970 (55 years) |
Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director | 732.49k | 1975 (50 years) |
Mr. Alexander Zurcher | COO & Member of Management Board | N/A | 1975 (50 years) |
Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior VP Legal & Business Development | N/A | |
Ms. Anne Goubier D.V.M., Ph.D. | Senior Vice President of Research & Early Development | N/A | |
Dr. Pamela A. Trail Ph.D. | Strategic Consultant | N/A | 1956 (69 years) |
Mr. Robert Hendriks | Senior VP of Finance | N/A |
Address: Switzerland, Schlieren, Wagistrasse 14 - open in Google maps, open in Yandex maps
Website: https://www.molecularpartners.com
Website: https://www.molecularpartners.com